176 related articles for article (PubMed ID: 38652565)
1. Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.
Barata P; Gulati S; Elliott A; Hammers HJ; Burgess EF; Gartrell BA; Darabi S; Bilen MA; Basu A; Geynisman DM; Dawson NA; Zibelman MR; Zhang T; Wei S; Ryan CJ; Heath EI; Poorman KA; Nabhan C; McKay RR
J Clin Invest; 2024 Apr; 134(11):. PubMed ID: 38652565
[TBL] [Abstract][Full Text] [Related]
2. Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma.
Donskov F; Pinto CA; Predoiu R; Fox C; Georgsen JB; Skaarup K; Burcu M; Perini R; Steiniche T
Acta Oncol; 2022 Oct; 61(10):1268-1277. PubMed ID: 36112410
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities.
Zarrabi K; Walzer E; Zibelman M
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359554
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiles of renal cell carcinoma in a small Chinese cohort.
Tai S; Xu DD; Yu Z; Guan Y; Yin S; Xiao J; Xue S; Liang C
Front Oncol; 2023; 13():1095775. PubMed ID: 37427096
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
6. Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options.
Wilson NR; Acikgoz Y; Hasanov E
Int J Cancer; 2024 Mar; 154(6):947-961. PubMed ID: 37823185
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.
Izumi K; Inoue M; Washino S; Shirotake S; Kagawa M; Takeshita H; Miura Y; Hyodo Y; Oyama M; Kawakami S; Miyagawa T; Saito K; Kageyama Y
Int J Urol; 2023 Sep; 30(9):714-721. PubMed ID: 36541136
[TBL] [Abstract][Full Text] [Related]
8. Characterizing Tumor Thrombus Arising from Non-Clear Cell Renal Cell Carcinoma.
Rabinowitz MJ; Esfandiary T; Cheaib J; Patel SH; Alam R; Metcalf M; Enikeev D; Pierorazio PM; Ged YMA; Allaf ME; Singla N
Eur Urol Open Sci; 2022 Sep; 43():28-34. PubMed ID: 36353070
[TBL] [Abstract][Full Text] [Related]
9. Clear cell and non-clear cell renal cell carcinoma in young adults: clinicopathological features, survival outcomes and prognostic factors.
Xue Z; Tang S; Ou J; Fang Y; Qiu M; Hong K; Tian X; Zhang H; Liu C; Ma L; Zhang S
World J Urol; 2024 May; 42(1):364. PubMed ID: 38819448
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database.
Koguchi T; Naito S; Hatakeyama S; Numakura K; Muto Y; Kato R; Kojima T; Kawasaki Y; Morozumi K; Kandori S; Kawamura S; Nishiyama H; Ito A; Habuchi T; Obara W; Ohyama C; Tsuchiya N; Kojima Y
Cancer Med; 2023 Nov; 12(22):20677-20689. PubMed ID: 37905674
[TBL] [Abstract][Full Text] [Related]
11. Advanced Non-Clear Cell Renal Cell Carcinoma Treatments and Survival: A Real-World Single-Centre Experience.
Bimbatti D; Pierantoni F; Lai E; Ballestrin M; Cavasin N; Erbetta E; De Toni C; Basso U; Maruzzo M
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686629
[TBL] [Abstract][Full Text] [Related]
12. The role of immunotherapy in non-clear cell renal cell carcinoma.
Climent C; Soriano S; Bonfill T; Lopez N; Rodriguez M; Sierra M; Andreu P; Fragio M; Busquets M; Carrasco A; Cano O; Seguí MA; Gallardo E
Front Oncol; 2023; 13():941835. PubMed ID: 36816976
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
Chahoud J; Msaouel P; Campbell MT; Bathala T; Xiao L; Gao J; Zurita AJ; Shah AY; Jonasch E; Sharma P; Tannir NM
Oncologist; 2020 Mar; 25(3):252-258. PubMed ID: 32162795
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
Pal SK; McGregor B; Suárez C; Tsao CK; Kelly W; Vaishampayan U; Pagliaro L; Maughan BL; Loriot Y; Castellano D; Srinivas S; McKay RR; Dreicer R; Hutson T; Dubey S; Werneke S; Panneerselvam A; Curran D; Scheffold C; Choueiri TK; Agarwal N
J Clin Oncol; 2021 Nov; 39(33):3725-3736. PubMed ID: 34491815
[TBL] [Abstract][Full Text] [Related]
15. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
16. Associations between T cell infiltration, T cell receptor clonality, histology and recurrence in renal cell carcinoma.
Gadot M; Gal M; Dobosz P; Dotan Z; Ramon J; Berger R; Avni D; Fridman E; Leibowitz R
Clin Exp Immunol; 2021 Aug; 205(2):160-168. PubMed ID: 33899933
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
Front Immunol; 2021; 12():734646. PubMed ID: 34795663
[TBL] [Abstract][Full Text] [Related]
19. Contemporary Drug Therapy for Renal Cell Carcinoma- Evidence Accumulation and Histological Implications in Treatment Strategy.
Yamana K; Ohashi R; Tomita Y
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359359
[TBL] [Abstract][Full Text] [Related]
20. Percutaneous radiofrequency ablation for renal cell carcinoma vs. partial nephrectomy: Comparison of long-term oncologic outcomes in both clear cell and non-clear cell of the most common subtype.
Liu N; Huang D; Cheng X; Chong Y; Wang W; Gan W; Guo H
Urol Oncol; 2017 Aug; 35(8):530.e1-530.e6. PubMed ID: 28408296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
